Webb Penelope M, Hopper John L, Newman Beth, Chen Xiaoqing, Kelemen Livia, Giles Graham G, Southey Melissa C, Chenevix-Trench Georgia, Spurdle Amanda B
Population and Clinical Sciences Division, Queensland Institute of Medical Research and University of Queensland, Brisbane, Queensland, Australia.
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):319-23. doi: 10.1158/1055-9965.EPI-04-0335.
Deficiencies in DNA repair have been hypothesized to increase cancer risk and excess cancer incidence is a feature of inherited diseases caused by defects in DNA damage recognition and repair. We investigated, using a case-control design, whether the double-strand break repair gene polymorphisms RAD51 5' untranslated region -135 G > C, XRCC2 R188H G > A, and XRCC3 T241M C > T were associated with risk of breast or ovarian cancer in Australian women. Sample sets included 1,456 breast cancer cases and 793 age-matched controls ages under 60 years of age, 549 incident ovarian cancer cases, and 335 controls of similar age distribution. For the total sample and the subsample of Caucasian women, there were no significant differences in genotype distribution between breast cancer cases and controls or between ovarian cancer cases and combined control groups. The crude odds ratios (OR) and 95% confidence intervals (95% CI) associated with the RAD51 GC/CC genotype frequency was OR, 1.10; 95% CI, 0.80-1.41 for breast cancer and OR, 1.22; 95% CI, 0.92-1.62 for ovarian cancer. Similarly, there were no increased risks associated with the XRCC2 GA/AA genotype (OR, 0.98; 95% CI, 0.76-1.26 for breast cancer and OR, 0.93; 95% CI, 0.69-1.25 for ovarian cancer) or the XRCC3 CT/TT genotype (OR, 0.92; 95% CI, 0.77-1.10 for breast cancer and OR, 0.87; 95% CI, 0.71-1.08 for ovarian cancer). Results were little changed after adjustment for age and other measured risk factors. Although there was little statistical power to detect modest increases in risk for the homozygote variant genotypes, particularly for the rare RAD51 and XRCC2 variants, the data suggest that none of these variants play a major role in the etiology of breast or ovarian cancer.
DNA修复缺陷被认为会增加癌症风险,而癌症发病率过高是由DNA损伤识别和修复缺陷引起的遗传性疾病的一个特征。我们采用病例对照设计,研究双链断裂修复基因多态性RAD51 5'非翻译区-135 G>C、XRCC2 R188H G>A和XRCC3 T241M C>T是否与澳大利亚女性患乳腺癌或卵巢癌的风险相关。样本集包括1456例60岁以下的乳腺癌病例和793例年龄匹配的对照,549例卵巢癌新发病例和335例年龄分布相似的对照。对于总样本和白人女性子样本,乳腺癌病例与对照之间或卵巢癌病例与合并对照组之间的基因型分布没有显著差异。与RAD51 GC/CC基因型频率相关的粗比值比(OR)和95%置信区间(95%CI)为:乳腺癌的OR为1.10;95%CI为0.80-1.41,卵巢癌的OR为1.22;95%CI为0.92-1.62。同样,与XRCC2 GA/AA基因型(乳腺癌的OR为0.98;95%CI为0.76-1.26,卵巢癌的OR为0.93;95%CI为0.69-1.25)或XRCC3 CT/TT基因型(乳腺癌的OR为0.92;95%CI为0.77-1.10,卵巢癌的OR为0.87;95%CI为0.71-1.08)无关的风险也没有增加。在调整年龄和其他测量的风险因素后,结果变化不大。尽管检测纯合子变异基因型风险的适度增加的统计能力很小,特别是对于罕见的RAD51和XRCC2变异,但数据表明这些变异均未在乳腺癌或卵巢癌的病因中起主要作用。